Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Clin Chem Lab Med ; 62(6): 1109-1117, 2024 May 27.
Artigo em Inglês | MEDLINE | ID: mdl-38290722

RESUMO

OBJECTIVES: Seizures (SZ) are one of the main complications occurring in infants undergoing therapeutic hypothermia (TH) due to perinatal asphyxia (PA) and hypoxic ischemic encephalopathy (HIE). Phenobarbital (PB) is the first-line therapeutic strategy, although data on its potential side-effects need elucidation. We investigated whether: i) PB administration in PA-HIE TH-treated infants affects S100B urine levels, and ii) S100B could be a reliable early predictor of SZ. METHODS: We performed a prospective case-control study in 88 PA-HIE TH infants, complicated (n=44) or not (n=44) by SZ requiring PB treatment. S100B urine levels were measured at 11 predetermined monitoring time-points from first void up to 96-h from birth. Standard-of-care monitoring parameters were also recorded. RESULTS: S100B significantly increased in the first 24-h independently from HIE severity in the cases who later developed SZ and requested PB treatment. ROC curve analysis showed that S100B, as SZ predictor, at a cut-off of 2.78 µg/L achieved a sensitivity/specificity of 63 and 84 %, positive/negative predictive values of 83 and 64 %. CONCLUSIONS: The present results offer additional support to the usefulness of S100B as a trustable diagnostic tool in the clinical daily monitoring of therapeutic and pharmacological procedures in infants complicated by PA-HIE.


Assuntos
Asfixia Neonatal , Hipotermia Induzida , Subunidade beta da Proteína Ligante de Cálcio S100 , Convulsões , Humanos , Subunidade beta da Proteína Ligante de Cálcio S100/urina , Convulsões/urina , Convulsões/diagnóstico , Convulsões/tratamento farmacológico , Masculino , Recém-Nascido , Feminino , Estudos de Casos e Controles , Estudos Prospectivos , Asfixia Neonatal/urina , Asfixia Neonatal/terapia , Asfixia Neonatal/complicações , Curva ROC , Hipóxia-Isquemia Encefálica/urina , Hipóxia-Isquemia Encefálica/terapia , Hipóxia-Isquemia Encefálica/diagnóstico , Fenobarbital/uso terapêutico , Lactente , Biomarcadores/urina
2.
Clin Chem Lab Med ; 60(8): 1136-1144, 2022 07 26.
Artigo em Inglês | MEDLINE | ID: mdl-35562321

RESUMO

Perinatal sepsis constitutes a medical emergency and is still one of the major causes of mortality and morbidity. The possibility of an early diagnosis of sepsis is still debated and controversial. In particular, clinical symptoms can be hidden by the association of sepsis with other perinatal diseases and/or by therapeutic strategies performed. In this context, there is evidence that the accuracy of standard of care diagnostic parameters (i.e. blood culture, C-reactive protein, procalcitonin) can be biased by additional confounding factors (gestational age, birth-weight, acute-chronic hypoxia). Therefore, the inclusion in clinical daily practice of new biomarkers of sepsis is of utmost importance. Of a panel of biomarkers, Presepsin (P-SEP) plays an important role in the development and response of the immune system and as an early marker of sepsis both in adult and pediatric patients. Therefore, in the present review we aim to offer an overview of the role of P-SEP in the early detection of perinatal sepsis as a trustworthy marker according to actual statements of official international institutions. Future perspectives regard the possibility of a longitudinal non-invasive biological fluids P-SEP assessment thus limiting the sample stress in high risk newborns.


Assuntos
Doenças do Recém-Nascido , Sepse , Adulto , Biomarcadores , Proteína C-Reativa/análise , Criança , Feminino , Humanos , Recém-Nascido , Receptores de Lipopolissacarídeos , Fragmentos de Peptídeos , Gravidez , Pró-Calcitonina , Sepse/diagnóstico
3.
Pediatr Allergy Immunol ; 14(1): 42-9, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12603710

RESUMO

A multivariate analysis using a logistic regression model evaluated odds ratio (OR) and 95% confidence limits (95% CL) of pediatrician-diagnosed wheezing respiratory illness in 75 infants with perinatal human immunodeficiency virus-type 1 (HIV-1) infection, 205 uninfected infants of HIV-1 infected mothers, and 1780 infants of HIV-1 uninfected mothers. Infants were prospectively followed-up for the first 2 years of life. Covariates were risk factors for wheezing respiratory illness (preterm delivery, low birth weight, maternal smoking, formula feeding, and neonatal respiratory disorders). Maternal use of illicit drugs in pregnancy, antiretroviral treatment in pregnancy, maternal HIV-1-related clinical condition at the time of delivery were also included in the models when infants of HIV-1 infected mothers were taken into account. Although the frequency of risk factors for wheezing respiratory illness was higher in infants of HIV-1 infected than in those of uninfected mothers, HIV-1 infection emerged as a protective factor [OR: 0.001 (95% CL: 0.0001-0.01); p < 0.001]. The frequency of risk factors was similarly high among infants of infected mothers, but OR was lower in HIV-1 infected than in uninfected infants of infected mothers (0.005; 95% CL: 0.0004-0.06; p < 0.001). Finally, OR was higher in uninfected infants of HIV-1 infected mothers (who evidenced a higher frequency of risk factors) than in infants of HIV-1 uninfected mothers (9.97; 95% CL: 4.87-20.40; p < 0.001). Understanding the reason why HIV-1 protects against wheezing respiratory illness could shed light on the immunologic and inflammatory mechanisms of airway obstruction.


Assuntos
Infecções por HIV/imunologia , Infecções por HIV/microbiologia , HIV-1 , Doenças do Recém-Nascido/imunologia , Doenças do Recém-Nascido/microbiologia , Complicações Infecciosas na Gravidez/imunologia , Complicações Infecciosas na Gravidez/microbiologia , Sons Respiratórios/imunologia , Adulto , Obstrução das Vias Respiratórias/epidemiologia , Obstrução das Vias Respiratórias/imunologia , Obstrução das Vias Respiratórias/microbiologia , Anti-Infecciosos/uso terapêutico , Terapia Antirretroviral de Alta Atividade , Quimioprevenção , Feminino , Seguimentos , Infecções por HIV/tratamento farmacológico , Humanos , Bem-Estar do Lactente , Recém-Nascido de Baixo Peso/imunologia , Recém-Nascido , Doenças do Recém-Nascido/tratamento farmacológico , Masculino , Bem-Estar Materno , Relações Mãe-Filho , Pneumonia por Pneumocystis/tratamento farmacológico , Pneumonia por Pneumocystis/imunologia , Pneumonia por Pneumocystis/microbiologia , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológico , Estudos Prospectivos , Inibidores de Proteases/uso terapêutico , Inibidores da Transcriptase Reversa/uso terapêutico , Fatores de Risco , Índice de Gravidade de Doença , Resultado do Tratamento , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA